Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

746.36 -6.26 (-0.83%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

58 59 Next >

Why Regeneron (REGN) Shares Are Falling Today

May 30, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic...

Via StockStory

Topics Artificial Intelligence

Discover which S&P500 stocks are making waves on Friday. ↗

May 30, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.

Via Chartmill

Regeneron Pharmaceuticals Unusual Options Activity For May 30 ↗

May 30, 2025

Via Benzinga

Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗

May 30, 2025

Via Benzinga

Unity Stock Jumps On Upgrade While Regeneron, Cooper Companies Tank On Downgrades – Top Wall Street Analyst Calls Today ↗

May 30, 2025

Jefferies upgraded Unity’s stock to ‘Buy’ from ‘Hold’ with a price target hike to $29 from $22.

Via Stocktwits

Topics ETFs Economy Stocks

Friday's session: gap up and gap down stock in the S&P500 index ↗

May 30, 2025

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends.

Via Chartmill

Traders are paying attention to the gapping stocks in Friday's session. ↗

May 30, 2025

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 30, 2025

Via Benzinga

Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure ↗

May 30, 2025

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Via Investor's Business Daily

These S&P500 stocks are moving in today's pre-market session ↗

May 30, 2025

Pre-market stock analysis of S&P500 stocks on 2025-05-30: top gainers and losers in today's session.

Via Chartmill

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data ↗

May 30, 2025

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Via Benzinga

Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗

May 30, 2025

Via Benzinga

Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment ↗

May 30, 2025

Both trials were conducted during the COVID-19 pandemic, a factor the companies said may have influenced the outcomes.

Via Stocktwits

Topics Government Stocks

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

May 30, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar

May 30, 2025

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an...

Via StockStory

The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. ↗

May 29, 2025

Via The Motley Fool

Topics Artificial Intelligence Bankruptcy

10 Health Care Stocks Whale Activity In Today's Session ↗

May 28, 2025

Via Benzinga

3 Value Stocks with Questionable Fundamentals

May 27, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Does the 23andMe Acquisition Make Regeneron a Buy Now? ↗

May 24, 2025

Via The Motley Fool

Topics Bankruptcy

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

May 22, 2025

Via Benzinga

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

May 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

3 Cash-Producing Stocks in Hot Water

May 21, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

What's going on in today's session: S&P500 movers ↗

May 20, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal ↗

May 19, 2025

Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025.

Via Benzinga

Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts ↗

May 19, 2025

Upon closing of the deal, 23andMe will be operated as a wholly owned direct or indirect unit of Regeneron and will continue operations as a personal genomics service.

Via Stocktwits

Topics Artificial Intelligence Bankruptcy

23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction ↗

May 19, 2025

The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank.

Via Investor's Business Daily

Topics Bankruptcy

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

May 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

May 19, 2025

From 23andMe, Inc.

Via GlobeNewswire

3 Stocks That Will Profit From Trump's Drug Price Cut ↗

May 16, 2025

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Via Benzinga

Topics Government

75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

May 16, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today